Chimeric Receptors to STEAP1 and Methods Of Use Thereof
AssigneeAmgen Inc.
InventorOlivier NOLAN-STEVAUX
Life of this patent
Estimating the term…
Abstract
Antigen binding molecules, chimeric receptors, and engineered immune cells to STEAP1 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the STEAP1 antigen binding molecules and engineered immune cells.
Claims79
A chimeric antigen receptor comprising an antigen binding molecule that specifically binds to STEAP1, a costimulatory domain, and an activating domain that is a signaling domain of CD3 zeta, wherein the antigen binding molecule comprises:
- a) a variable heavy (VH) chain region comprising complementarity determining regions (“CDRs”) 1, 2, and 3 with amino acid sequences SEQ ID NO:
- 89, SEQ ID NO:
- 90, SEQ ID NO:
- 91, respectively, and a variable light (VL) chain region comprising CDRs 1, 2, and 3 with amino acid sequences SEQ ID NO:
- 94, SEQ ID NO:
- 95, SEQ ID NO:
- 96, respectively;
- or
- b) a VH region of SEQ ID NO:
- 88 and a VL region of SEQ ID NO:
- 93;
- or
- c) a VH chain region comprising complementarity determining regions (“CDRs”) 1, 2, and 3 with amino acid sequences SEQ ID NO:
- 99, SEQ ID NO:
- 100, SEQ ID NO:
- 101, respectively, and VL chain region comprising CDRs 1, 2, and 3 with amino acid sequences SEQ ID NO:
- 104, SEQ ID NO:
- 105, SEQ ID NO:
- 106, respectively;
- or
- d) a VH region of SEQ ID NO:
- 98 and a VL region of SEQ ID NO:
- 103;
- or
- e) a VH chain region comprising complementarity determining regions (“CDRs”) 1, 2, and 3 with amino acid sequences SEQ ID NO:
- 109, SEQ ID NO:
- 110, SEQ ID NO:
- 111, respectively, and VL chain region comprising CDRs 1, 2, and 3 with amino acid sequences SEQ ID NO:
- 114, SEQ ID NO:
- 115, SEQ ID NO:
- 116, respectively;
- or
- f) a VH region of SEQ ID NO:
- 108 and a VL region of SEQ ID NO:
- 113;
- or
- g) a VH chain region comprising complementarity determining regions (“CDRs”) 1, 2, and 3 with amino acid sequences SEQ ID NO:
- 119, SEQ ID NO:
- 120, SEQ ID NO:
- 121, respectively, and VL chain region comprising CDRs 1, 2, and 3 with amino acid sequences SEQ ID NO:
- 124, SEQ ID NO:
- 125, SEQ ID NO:
- 126, respectively;
- or
- a VH region of SEQ ID NO:
- 118 and a VL region of SEQ ID NO:
- 123;
- or
- i) a VH chain region comprising complementarity determining regions (“CDRs”) 1, 2, and 3 with amino acid sequences SEQ ID NO:
- 129, SEQ ID NO:
- 130, SEQ ID NO:
- 131, respectively, and VL chain region comprising CDRs 1, 2, and 3 with amino acid sequences SEQ ID NO:
- 134, SEQ ID NO:
- 135, SEQ ID NO:
- 136, respectively;
- or
- j) a VH region of SEQ ID NO:
- 128 and a VL region of SEQ ID NO:
- 133;
- or
- k) a VH chain region comprising complementarity determining regions (“CDRs”) 1, 2, and 3 with amino acid sequences SEQ ID NO:
- 139, SEQ ID NO:
- 140, SEQ ID NO:
- 141, respectively, and VL chain region comprising CDRs 1, 2, and 3 with amino acid sequences SEQ ID NO:
- 144, SEQ ID NO:
- 145, SEQ ID NO:
- 166, respectively;
- or
- a VH region of SEQ ID NO:
- 138 and a VL region of SEQ ID NO:
- 133;
- wherein the VH and VL region is linked by at least one linker;
- and
- wherein the costimulatory domain comprises a CD28 costimulatory domain or a CD8 costimulatory domain.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:
- 18, SEQ ID NO:
- 20, SEQ ID NO:
- 22, SEQ ID NO:
- 24, SEQ ID NO:
- 26, SEQ ID NO:
- 28, SEQ ID NO:
- 30, SEQ ID NO:
- 32, SEQ ID NO:
- 34, SEQ ID NO:
- 36, SEQ ID NO:
- 38, SEQ ID NO:
- 40, SEQ ID NO:
- 42, SEQ ID NO:
- 44, SEQ ID NO:
- 46, SEQ ID NO:
- 48, SEQ ID NO:
- 50, SEQ ID NO:
- 52, SEQ ID NO:
- 54, SEQ ID NO:
- 56, SEQ ID NO:
- 58, SEQ ID NO:
- 60, SEQ ID NO:
- 62, SEQ ID NO:
- 64, SEQ ID NO:
- 66, SEQ ID NO:
- 68, SEQ ID NO:
- 70, SEQ ID NO:
- 72, SEQ ID NO:
- 74, or SEQ ID NO:
- 76.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.